目的：为调脂药的采购供应和临床合理使用提供参考。方法：对北京、成都、广州、杭州、上海、天津六地区74 家医院2013

年159 506 例患者进行流行病学调查，统计并分析调脂药的销售金额、用药频度、日均费用（DDC）、实际日均剂量及排序比。结

果：综合各地区，高脂血症患病率较高，为29.56％，呈地域性分布和年轻化趋势，伴有高血压、糖尿病及冠心病的患者患病率更

高。阿托伐他汀使用量最大，但DDC也较高；相比之下，瑞舒伐他汀更具有市场优势；辛伐他汀DDC较低，更适用于经济受限患

者。除北京、天津用药剂量较大外，其他地区多低于限定日剂量。结论：他汀类主导了调脂药市场，新型调脂药上市及联合用药为

治疗提供了新选择。

OBJECTIVE：To provide reference for drug procurement and supply and rational use of lipid-regulating agents.

METHODS：The epidemiological investigation was carried out among 159 506 cases from 74 hospitals in Beijing，Chengdu，

Guangzhou，Hangzhou，Shanghai and Tianjin in 2013. The utilization of lipid-regulating agents was analyzed statistically in respects

of purchase value，DDDs，DDC，actual average daily dose and sort ratio. RESULTS：The prevalence rate of hyperlipidemia

was relatively high，accounting for 29.56％ and showing a tendency of regional distribution and young age in all regions. The patients

with hypertension，diabetes and coronary heart disease had a higher incidence to suffer from hyperlipidemia. The use of atorvastatin

was in the first place，but it also had a higher DDC；while rosuvastatin hasd the advantage over aorvastatin in drug market.

Simvastatin had a lower DDC and was more suitable for the patients with low income. The doses of lipid-regulating agents in other

regions were lower than DDD except for those in Beijing and Tianjin. CONCLUSIONS：Statins dominate the lipid-regulating

agents market. But new lipid-regulating agents and drug combination provide a new choice for clinical treatment.